Industry Satellite Symposia

The American Society for Radiation Oncology (ASTRO) has reviewed and approved these symposia as appropriate for presentation as an Industry Satellite Symposium. The symposia constitute the content and views of the provider and are not part of the official ASTRO Annual Meeting program.

Sunday, October 1, 2023

6:00 p.m. - 8:00 p.m. | Tumor Treating Fields as an Innovative Modality of Cancer Therapy: From CNS to Thoracic Malignancies and Beyond

Location: Hilton San Diego Bayfront
Indigo Ballroom BC, Level 2
1 Park Boulevard
San Diego, CA

6:00 p.m. - 6:30 p.m.: Registration and Dinner
6:30 p.m. - 8:00 p.m.: Symposium

Please visit website for more information or to register.

CME Credits:

Physicians
PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Target Audience: This activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, neuro-oncologists, advanced practice clinicians, and other health care professionals involved in the management of solid tumors.

Learning Objectives: 

Upon completion of this activity, participants should be able to:

• Describe the mechanistic rationale and evidence supporting the use of TTFields for the treatment of patients with CNS, thoracic and other aggressive solid tumors.
• Integrate TTFields into multimodal management protocols for appropriately selected patients with CNS, thoracic and other solid malignancies.
• Devise team-based strategies designed to mitigate and manage adverse events associated with TTFields to improve outcomes in patients with difficult-to-treat cancers.

Key Reasons to Attend:

• Learn how to adapt your radiation oncology practice to encompass expertise in the delivery of TTFields therapy, working together with medical oncology, neuro-oncology and other disciplines.
• Dispel misconceptions related to the use of TTFields. Expert faculty will discuss the latest evidence on the efficacy, safety and quality of life possible with this modality across approved and emerging indications.
• Prepare for the next wave of progress in clinically challenging solid tumors of the CNS and beyond, including glioblastoma, brain metastases, NSCLC and pancreatic cancer.

Schedule:

• 6:00 p.m. - 6:30 p.m.: Registration and Dinner
• 6:30 p.m. - 8:00 p.m.: In-Person and Virtual Symposium
  • Seminar 1: Illuminating the Expanding Role of TTFields as a Component of Multimodal Management of CNS Cancers as Supported by Emerging Real-World Evidence
  • Seminar 2: Shining a Light on the Present and Future of TTFields as a Component of Multimodal Treatment of Thoracic Malignancies
  • Seminar 3: A Bright Path for TTFields – How Can Multimodal Approaches Extend Survival in Other Clinically Challenging Solid Tumors?
  • Symposium Summary and Audience Q&A
• 8:00 p.m.: Adjourn

Faculty:

1. Erik P. Sulman, MD, PhD, NYU Langone Health, New York
2. Zachary D. Horne, MD, Allegheny Health Network Cancer Institute, Pittsburgh
3. Ticiana Leal, MD, Winship Cancer Institute, Emory School of Medicine, Atlanta

This activity is supported by an educational grant from Novocure, Inc.

Monday, October 2, 2023

6:30 p.m. - 7:30 p.m. | Revolutionary Approaches to Improving Outcomes in Unresected LA SCCHN
CME-Accredited Symposium

Location: Manchester Grand Hyatt San Diego
Seaport Ballroom AB
1 Market Place
San Diego, CA

6:15 p.m. - 6:30 p.m.: Registration and Dinner
6:30 p.m. - 7:30 p.m.: Symposium

Please visit website for more information or to register.

CME Credits: Global Learning Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target audience: This activity is designed to meet the educational needs of medical oncologists, pathologists, radiation oncologists and other health care professionals treating patients with head and neck cancers.

Learning Objectives:

1. Identify and explain the various factors that contribute to the recurrence or progression of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
2. Evaluate the risks, benefits, and limitations of currently available treatment options for managing patients with locally advanced SCCHN, and develop a comprehensive management plan based on patient-specific factors.
3. Analyze and compare the mechanisms of action of agents currently under investigation for the treatment of locally advanced SCCHN with those of currently available treatment options, and discuss potential implications for patient care.
4. Assess the therapeutic potential of emerging agents being investigated for the management of locally advanced SCCHN, and discuss their potential impact on current treatment paradigms.
5. Compare the definitions, benefits, and limitations of early endpoints used in oncology trials and their relation to patient outcomes
6. Describe the evidence, rationale, and clinical significance of, early endpoints used in ongoing clinical trials in LA SCCHN

Topics:

Faculty:

1. Ezra Cohen, MD, University of California, San Diego Health
2. Kevin Harrington, MBBS, PhD, The Institute of Cancer Research
3. Deborah J. Wong, MD, PhD, UCLA Health

This activity is supported by an independent educational grant from EMD Serono, Inc. EMD Serono, Inc. is the health care business of Merck KGaA, Darmstadt, Germany.